Merck & Co pens $340m pain drug deal with KCL and WellcomeMerck & Co has announced a deal with King’s College London (KCL) and Wellcome to investigate a new Share XMerck & Co pens $340m pain drug deal with KCL and Wellcomehttps://pharmaphorum.com/news/merck-co-pens-340m-pain-drug-deal-with-kcl-and-wellcome/
Keytruda could get patient-friendly 6 week dosing schedule in EUUS-based Merck & Co is putting further pressure on its arch-rival Bristol-Myers Squibb with a potential new six-week Share XKeytruda could get patient-friendly 6 week dosing schedule in EUhttps://pharmaphorum.com/news/keytruda-could-get-patient-friendly-6-week-dosing-schedule-in-eu/
Pharma CEOs grilled by US Senators over drug pricesPharma bosses faced a grilling from the US Senate’s Finance Committee over the high price of branded prescription Share XPharma CEOs grilled by US Senators over drug priceshttps://pharmaphorum.com/news/pharma-ceos-grilled-by-us-senators-over-drug-prices/
AZ/Merck & Co’s Lynparza delays spread of pancreatic cancerAstraZeneca and Merck & Co’s Lynparza could offer a new option for certain patients with pancreatic cancer after Share XAZ/Merck & Co’s Lynparza delays spread of pancreatic cancerhttps://pharmaphorum.com/news/az-merck-cos-lynparza-delays-spread-of-pancreatic-cancer/
Merck’s Keytruda gets boost in kidney and head and neck cancerMerck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Share XMerck’s Keytruda gets boost in kidney and head and neck cancerhttps://pharmaphorum.com/news/mercks-keytruda-gets-boost-in-kidney-and-head-and-neck-cancer/
FDA accepts Merck & Co’s two new antibacterial drug applicationsThe FDA has accepted two new antibacterial drug applications from Merck & Co, both of which have received Share XFDA accepts Merck & Co’s two new antibacterial drug applicationshttps://pharmaphorum.com/news/fda-accepts-merck-cos-two-new-antibacterial-drug-applications/
FDA approves Samsung/Merck & Co’s Herceptin biosimilarThe FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck Share XFDA approves Samsung/Merck & Co’s Herceptin biosimilarhttps://pharmaphorum.com/news/fda-approves-samsung-merck-cos-herceptin-biosimilar/
FDA extends review of Merck & Co’s Keytruda in lung cancer useUS regulators have pushed back the deadline for their review of Merck & Co’s immunotherapy Keytruda in certain Share XFDA extends review of Merck & Co’s Keytruda in lung cancer usehttps://pharmaphorum.com/news/fda-review-merck-keytruda-lung-cancer/
AZ/Merck & Co get new US use for ovarian cancer drugAfter several disappointments this year AstraZeneca has ended 2018 on a positive note, gaining a new use for Share XAZ/Merck & Co get new US use for ovarian cancer drughttps://pharmaphorum.com/news/astrazeneca-merck-lynparza-roxadustat/
